Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Elliott

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Bone Marrow Transplantation|March 9, 2010
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignanciesS G Holtan, W J Hogan, M A Elliott, et al.
Blood Cancer Journal|January 18, 2022
European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall responseK H Begna, J Kittur, N Gangat, et al.
Molecular Psychiatry|January 25, 2017
Glutamate imaging (GluCEST) reveals lower brain GluCEST contrast in patients on the psychosis spectrumD R Roalf, R P R Nanga, P E Rupert, et al.
Bone Marrow Transplantation|April 11, 2006
Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemiaM A Elliott, A Tefferi, W J Hogan, et al.
Blood Cancer Journal|April 8, 2022
Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3"K H Begna, X Xu, N Gangat, et al.
Cerebral Cortex (New York, N.Y. : 1991)|September 25, 2016
Comparison of In Vivo and Ex Vivo MRI of the Human Hippocampal Formation in the Same SubjectsL E M Wisse, D H Adler, R Ittyerah, et al.
Bone Marrow Transplantation|May 4, 2010
Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilizationH V Naina, R K Pruthi, D J Inwards, et al.
Molecular Psychiatry|September 20, 2017
Common and dissociable regional cerebral blood flow differences associate with dimensions of psychopathology across categorical diagnosesA N Kaczkurkin, T M Moore, M E Calkins, et al.
Leukemia|November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaA Dispenzieri, G A Wiseman, M Q Lacy, et al.
Bone Marrow Transplantation|August 4, 2009
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinomaM R Litzow, P P Peethambaram, S L Safgren, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Bone Marrow Transplantation|March 9, 2010
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignanciesS G Holtan, W J Hogan, M A Elliott, et al.
Blood Cancer Journal|January 18, 2022
European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall responseK H Begna, J Kittur, N Gangat, et al.
Molecular Psychiatry|January 25, 2017
Glutamate imaging (GluCEST) reveals lower brain GluCEST contrast in patients on the psychosis spectrumD R Roalf, R P R Nanga, P E Rupert, et al.
Bone Marrow Transplantation|April 11, 2006
Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemiaM A Elliott, A Tefferi, W J Hogan, et al.
Blood Cancer Journal|April 8, 2022
Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3"K H Begna, X Xu, N Gangat, et al.
Cerebral Cortex (New York, N.Y. : 1991)|September 25, 2016
Comparison of In Vivo and Ex Vivo MRI of the Human Hippocampal Formation in the Same SubjectsL E M Wisse, D H Adler, R Ittyerah, et al.
Bone Marrow Transplantation|May 4, 2010
Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilizationH V Naina, R K Pruthi, D J Inwards, et al.
Molecular Psychiatry|September 20, 2017
Common and dissociable regional cerebral blood flow differences associate with dimensions of psychopathology across categorical diagnosesA N Kaczkurkin, T M Moore, M E Calkins, et al.
Leukemia|November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaA Dispenzieri, G A Wiseman, M Q Lacy, et al.
Bone Marrow Transplantation|August 4, 2009
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinomaM R Litzow, P P Peethambaram, S L Safgren, et al.
Pageof 10